Chemoprevention in Barrett's Esophagus: Current Status

Gastroenterology Clinics of North America

Volumn 44, Issue 2, 2015, Pages 391-413

  Zeb, Muhammad H ^a   Baruah, Anushka ^b   Kossak, Sarah K ^a   Buttar, Navtej S ^a  

^a MAYO CLINIC   (United States)

^b Jr Hospital of Cook County   (United States)

Author keywords

Barrett's esophagus; Chemoprevention; Chronic reflux; Esophageal adenocarcinoma

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; BILE SALT; CELECOXIB; EFLORNITHINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESOMEPRAZOLE; GASTRIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; METFORMIN; MYC PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORNITHINE DECARBOXYLASE INHIBITOR; PLACEBO; PROSTAGLANDIN E2; PROTON PUMP INHIBITOR; PUTRESCINE; S6 KINASE; SPERMIDINE; SPERMINE; STAT3 PROTEIN; SULINDAC; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; WNT PROTEIN; ANTIDIABETIC AGENT; BILE ACID; CYTOKINE; UNSATURATED FATTY ACID;

ARACHIDONIC ACID METABOLISM; BARRETT ESOPHAGUS; CANCER ADJUVANT THERAPY; CHEMOPROPHYLAXIS; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE MARKER; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; ENVIRONMENTAL EXPOSURE; ENZYME INHIBITION; EPIGENETICS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS DYSPLASIA; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; GENETIC POLYMORPHISM; HISTOPATHOLOGY; HUMAN; HYPERGASTRINEMIA; LOW DRUG DOSE; MALIGNANT TRANSFORMATION; MEDICAL RESEARCH; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MULTICENTER STUDY (TOPIC); NONHUMAN; OBESITY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PROSTAGLANDIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK REDUCTION; SMOKING; STOMACH ACID; ADENOCARCINOMA; COMPLICATION; DRUG DEVELOPMENT; ESOPHAGEAL NEOPLASMS; INFLAMMATION; METABOLISM; PATHOLOGY; PRECANCEROUS CONDITIONS; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BARRETT ESOPHAGUS; BILE ACIDS AND SALTS; CYTOKINES; DRUG DISCOVERY; ESOPHAGEAL NEOPLASMS; FATTY ACIDS, UNSATURATED; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; INFLAMMATION; METABOLIC SYNDROME X; METFORMIN; OBESITY; ORNITHINE DECARBOXYLASE INHIBITORS; PRECANCEROUS CONDITIONS; PROTON PUMP INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84929879338     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2015.02.009     Document Type: Review

References (152)

1. Falk G.W., Buttar N.S., Foster N.R., et al. Acombination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. Gastroenterology 2012, 143(4):917-926.e1.
2. Spechler S.J., Sharma P., Souza R.F., et al. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology 2011, 140:e18-e52. [quiz: e13].
3. Shaheen N., Ransohoff D.F. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA 2002, 287(15):1972-1981.
4. Hvid-Jensen F., Pedersen L., Drewes A.M., et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. NEngl J Med 2011, 365(15):1375-1383.
5. Bhat S., Coleman H.G., Yousef F., et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. JNatl Cancer Inst 2011, 103(13):1049-1057.
6. Desai T.K., Krishnan K., Samala N., et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012, 61(7):970-976.
7. Vaezi M.F., Richter J.E. Synergism of acid and duodenogastroesophageal reflux in complicated Barrett's esophagus. Surgery 1995, 117(6):699-704.
8. Nehra D., Howell P., Williams C.P., et al. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut 1999, 44(5):598-602.
9. Sontag S.J. The medical management of reflux esophagitis. Role of antacids and acid inhibition. Gastroenterol Clin North Am 1990, 19(3):683-712.
10. Theisen J., Nehra D., Citron D., et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. JGastrointest Surg 2000, 4(1):50-54.
11. Goldstein S.R., Yang G.Y., Curtis S.K., et al. Development of esophageal metaplasia and adenocarcinoma in a rat surgical model without the use of a carcinogen. Carcinogenesis 1997, 18(11):2265-2270.
12. Kawaura Y., Tatsuzawa Y., Wakabayashi T., et al. Immunohistochemical study of p53, c-erbB-2, and PCNA in Barrett's esophagus with dysplasia and adenocarcinoma arising from experimental acid or alkaline reflux model. JGastroenterol 2001, 36(9):595-600.
13. Gammon M.D., Schoenberg J.B., Ahsan H., et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. JNatl Cancer Inst 1997, 89(17):1277-1284.
14. Mirvish S.S. Studies on experimental animals involving surgical procedures and/or nitrosamine treatment related to the etiology of esophageal adenocarcinoma. Cancer Lett 1997, 117(2):161-174.
15. Menke-Pluymers M.B., Hop W.C., Dees J., et al. Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus. The Rotterdam Esophageal Tumor Study Group. Cancer 1993, 72(4):1155-1158.
16. Gray M.R., Donnelly R.J., Kingsnorth A.N. The role of smoking and alcohol in metaplasia and cancer risk in Barrett's columnar lined oesophagus. Gut 1993, 34(6):727-731.
17. Avidan B., Sonnenberg A., Schnell T.G., et al. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002, 97(8):1930-1936.
18. Bani-Hani K.E., Bani-Hani B.K., Martin I.G. Characteristics of patients with columnar-lined Barrett's esophagus and risk factors for progression to esophageal adenocarcinoma. World J Gastroenterol 2005, 11(43):6807-6814.
19. Forman D., Al-Dabbagh S., Doll R. Nitrates, nitrites and gastric cancer in Great Britain. Nature 1985, 313(6004):620-625.
20. Duncan C., Dougall H., Johnston P., et al. Chemical generation of nitric oxide in the mouth from the enterosalivary circulation of dietary nitrate. Nat Med 1995, 1(6):546-551.
21. Calmels S., Béréziat J.C., Ohshima H., et al. Bacterial formation of N-nitroso compounds from administered precursors in the rat stomach after omeprazole-induced achlorhydria. Carcinogenesis 1991, 12(3):435-439.
22. Spechler S.J. Carcinogenesis at the gastroesophageal junction: free radicals at the frontier. Gastroenterology 2002, 122(5):1518-1520.
23. Liu R.H., Hotchkiss J.H. Potential genotoxicity of chronically elevated nitric oxide: a review. Mutat Res 1995, 339(2):73-89.
24. Buttar N.S., Wang K.K., Anderson M.A., et al. The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an invitro study. JNatl Cancer Inst 2002, 94(6):422-429.
25. Buttar N.S., Wang K.K., Leontovich O., et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002, 122(4):1101-1112.
26. Buttar N.S., DeMars C.J., Lomberk G., et al. Distinct role of Kruppel-like factor 11 in the regulation of prostaglandin E2 biosynthesis. JBiol Chem 2010, 285(15):11433-11444.
27. Buttar N.S., Fernandez-Zapico M.E., Urrutia R. Key role of Kruppel-like factor proteins in pancreatic cancer and other gastrointestinal neoplasias. Curr Opin Gastroenterol 2006, 22(5):505-511.
28. Kaur B.S., Triadafilopoulos G. Acid- and bile-induced PGE(2) release and hyperproliferation in Barrett's esophagus are COX-2 and PKC-epsilon dependent. Am J Physiol Gastrointest Liver Physiol 2002, 283:G327-G334.
29. Souza R.F., Shewmake K., Pearson S., et al. Acid increases proliferation via ERK and p38 MAPK-mediated increases in cyclooxygenase-2 in Barrett's adenocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 2004, 287:G743-G748.
30. Buttar N.S., Wang K.K. Mechanisms of disease: carcinogenesis in Barrett's esophagus. Nat Clin Pract Gastroenterol Hepatol 2004, 1(2):106-112.
31. Tselepis C., Perry I., Dawson C., et al. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene 2002, 21(39):6071-6081.
32. Jankowski J., Hopwood D., Wormsley K.G. Flow-cytometric analysis of growth-regulatory peptides and their receptors in Barrett's oesophagus and oesophageal adenocarcinoma. Scand J Gastroenterol 1992, 27(2):147-154.
33. Jankowski J., Coghill G., Tregaskis B., et al. Epidermal growth factor in the oesophagus. Gut 1992, 33(11):1448-1453.
34. Jankowski J., Hopwood D., Wormsley K.G. Expression of epidermal growth factor, transforming growth factor alpha and their receptor in gastro-oesophageal diseases. Dig Dis 1993, 11(1):1-11.
35. Nishigaki H., Wada K., Tatsuguchi A., et al. ErbB2 without erbB3 expression in metaplastic columnar epithelium of Barrett's esophagus. Digestion 2004, 70(2):95-102.
36. Quante M., Bhagat G., Abrams J.A., et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell 2012, 21(1):36-51.
37. Kaur B.S., Ouatu-Lascar R., Omary M.B., et al. Bile salts induce or blunt cell proliferation in Barrett's esophagus in an acid-dependent fashion. Am J Physiol Gastrointest Liver Physiol 2000, 278:G1000-G1009.
38. Feagins L.A., Zhang H.Y., Zhang X., et al. Mechanisms of oxidant production in esophageal squamous cell and Barrett's cell lines. Am J Physiol Gastrointest Liver Physiol 2008, 294:G411-G417.
39. Rizvi S., Demars C.J., Comba A., et al. Combinatorial chemoprevention reveals a novel smoothened-independent role of GLI1 in esophageal carcinogenesis. Cancer Res 2010, 70(17):6787-6796.
40. Yen C.J., Izzo J.G., Lee D.F., et al. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. Cancer Res 2008, 68(8):2632-2640.
41. Song S., Guha S., Liu K., et al. COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signalling pathways in Barrett's oesophagus and oesophageal adenocarcinoma. Gut 2007, 56(11):1512-1521.
42. Fitzgerald R.C., Abdalla S., Onwuegbusi B.A., et al. Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut 2002, 51(3):316-322.
43. Fitzgerald R.C., Onwuegbusi B.A., Bajaj-Elliott M., et al. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut 2002, 50(4):451-459.
44. Dvorakova K., Payne C.M., Ramsey L., et al. Increased expression and secretion of interleukin-6 in patients with Barrett's esophagus. Clin Cancer Res 2004, 10(6):2020-2028.
45. Jankowski J., McMenemin R., Hopwood D., et al. Abnormal expression of growth regulatory factors in Barrett's oesophagus. Clin Sci (Lond) 1991, 81(5):663-668.
46. Venere M., Lathia J.D., Rich J.N. Growth factor receptors define cancer hierarchies. Cancer Cell 2013, 23(2):135-137.
47. van Hagen P., Biermann K., Boers J.E., et al. Human epidermal growth factor receptor 2 overexpression and amplification in endoscopic biopsies and resection specimens in esophageal and junctional adenocarcinoma. Dis Esophagus 2015, 13(4):665-672.
48. al-Kasspooles M., Moore J.H., Orringer M.B., et al. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 1993, 54(2):213-219.
49. Jankowski J., Coghill G., Hopwood D., et al. Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut 1992, 33(8):1033-1038.
50. Nakamura T., Nekarda H., Hoelscher A.H., et al. Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus. Cancer 1994, 73(7):1785-1794.
51. Hardwick R.H., Shepherd N.A., Moorghen M., et al. c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus. JClin Pathol 1995, 48(2):129-132.
52. Lagorce C., Fléjou J.F., Muzeau F., et al. Absence of c-Ki-ras gene mutation in malignant and premalignant Barrett's oesophagus. Clin Mol Pathol 1995, 48:M198-M199.
53. Zhang X., Yu C., Wilson K., et al. Malignant transformation of non-neoplastic Barrett's epithelial cells through well-defined genetic manipulations. PLoS One 2010, 5. [pii:e13093].
54. Clement G., Braunschweig R., Pasquier N., et al. Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus. Oncogene 2006, 25(21):3084-3092.
55. Clement G., Guilleret I., He B., et al. Epigenetic alteration of the Wnt inhibitory factor-1 promoter occurs early in the carcinogenesis of Barrett's esophagus. Cancer Sci 2008, 99(1):46-53.
56. Taniguchi H., Yamamoto H., Hirata T., et al. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 2005, 24(53):7946-7952.
57. Zou H., Molina J.R., Harrington J.J., et al. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus. Int J Cancer 2005, 116(4):584-591.
58. Clement G., Braunschweig R., Pasquier N., et al. Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation. JPathol 2006, 208(1):100-107.
59. Pegg A.E., Feith D.J. Polyamines and neoplastic growth. Biochem Soc Trans 2007, 35(Pt 2):295-299.
60. Brabender J., Lord R.V., Danenberg K.D., et al. Upregulation of ornithine decarboxylase mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. JGastrointest Surg 2001, 5(2):174-181. [discussion: 182].
61. Huo X., Juergens S., Zhang X., et al. Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-kappaB activation in benign Barrett's epithelial cells. Am J Physiol Gastrointest Liver Physiol 2011, 301:G278-G286.
62. Hanas J.S., Lerner M.R., Lightfoot S.A., et al. Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus. Cancer 1999, 86(5):756-763.
63. Barrett M.T., Sanchez C.A., Prevo L.J., et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999, 22(1):106-109.
64. Hormi-Carver K., Feagins L.A., Spechler S.J., et al. All trans-retinoic acid induces apoptosis via p38 and caspase pathways in metaplastic Barrett's cells. Am J Physiol Gastrointest Liver Physiol 2007, 292:G18-G27.
65. Akiyama J., Alexandre L., Baruah A., et al. Strategy for prevention of cancers of the esophagus. Ann N Y Acad Sci 2014, 1325(1):108-126.
66. Lee O.J., Schneider-Stock R., McChesney P.A., et al. Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis. Neoplasia 2005, 7(9):854-861.
67. Younes M., Schwartz M.R., Finnie D., et al. Overexpression of Fas ligand (FasL) during malignant transformation in the large bowel and in Barrett's metaplasia of the esophagus. Hum Pathol 1999, 30(11):1309-1313.
68. Younes M., Lechago J., Ertan A., et al. Decreased expression of Fas (CD95/APO1) associated with goblet cell metaplasia in Barrett's esophagus. Hum Pathol 2000, 31(4):434-438.
69. Lagergren J. Influence of obesity on the risk of esophageal disorders. Nat Rev Gastroenterol Hepatol 2011, 8(6):340-347.
70. Koppman J.S., Poggi L., Szomstein S., et al. Esophageal motility disorders in the morbidly obese population. Surg Endosc 2007, 21(5):761-764.
71. Ortiz V., Ponce M., Fernández A., et al. Value of heartburn for diagnosing gastroesophageal reflux disease in severely obese patients. Obesity (Silver Spring) 2006, 14(4):696-700.
72. Kuper M.A., Kramer K.M., Kirschniak A., et al. Dysfunction of the lower esophageal sphincter and dysmotility of the tubular esophagus in morbidly obese patients. Obes Surg 2009, 19(8):1143-1149.
73. McQuaid K.R., Laine L., Fennerty M.B., et al. Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. Aliment Pharmacol Ther 2011, 34(2):146-165.
74. Ryan A.M., Duong M., Healy L., et al. Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets. Cancer Epidemiol 2011, 35(4):309-319.
75. Renehan A.G., Roberts D.L., Dive C. Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem 2008, 114(1):71-83.
76. Lysaght J., Allott E.H., Donohoe C.L., et al. Tlymphocyte activation in visceral adipose tissue of patients with oesophageal adenocarcinoma. Br J Surg 2011, 98(7):964-974.
77. Damms-Machado A., Weser G., Bischoff S.C. Micronutrient deficiency in obese subjects undergoing low calorie diet. Nutr J 2012, 11:34.
78. Fountoulakis A., Martin I.G., White K.L., et al. Plasma and esophageal mucosal levels of vitamin C: role in the pathogenesis and neoplastic progression of Barrett's esophagus. Dig Dis Sci 2004, 49(6):914-919.
79. Otterstatter M.C., Brierley J.D., De P., et al. Esophageal cancer in Canada: trends according to morphology and anatomical location. Can J Gastroenterol 2012, 26(10):723-727.
80. Turati F., Tramacere I., La Vecchia C., et al. Ameta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. Ann Oncol 2013, 24(3):609-617.
81. Beddy P., Howard J., McMahon C., et al. Association of visceral adiposity with oesophageal and junctional adenocarcinomas. Br J Surg 2010, 97(7):1028-1034.
82. El-Serag H.B., Kvapil P., Hacken-Bitar J., et al. Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol 2005, 100(10):2151-2156.
83. Kendall B.J., Macdonald G.A., Hayward N.K., et al. The risk of Barrett's esophagus associated with abdominal obesity in males and females. Int J Cancer 2013, 132(9):2192-2199.
84. El-Serag H.B., Hashmi A., Garcia J., et al. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study. Gut 2014, 63(2):220-229.
85. Larsson S.C., Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr 2007, 86(3):556-565.
86. Iwao T., Toyonaga A., Kuboyama S., et al. Effects of omeprazole and lansoprazole on fasting and postprandial serum gastrin and serum pepsinogen A and C. Hepatogastroenterology 1995, 42(5):677-682.
87. Abdalla S.I., Lao-Sirieix P., Novelli M.R., et al. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis. Clin Cancer Res 2004, 10(14):4784-4792.
88. Haigh C.R., Attwood S.E., Thompson D.G., et al. Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. Gastroenterology 2003, 124(3):615-625.
89. Ohsawa T., Hirata W., Higichi S. Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level. Int J Clin Pharmacol Res 2002, 22(2):29-35.
90. Sampliner R.E. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The practice parameters committee of the American College of Gastroenterology. Am J Gastroenterol 1998, 93(7):1028-1032.
91. Reid B.J., Haggitt R.C., Rubin C.E., et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988, 19(2):166-178.
92. Cameron A.J., Carpenter H.A. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study. Am J Gastroenterol 1997, 92(4):586-591.
93. Reid B.J., Prevo L.J., Galipeau P.C., et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001, 96(10):2839-2848.
94. Rygiel A.M., van Baal J.W., Milano F., et al. Efficient automated assessment of genetic abnormalities detected by fluorescence in situ hybridization on brush cytology in a Barrett esophagus surveillance population. Cancer 2007, 109(10):1980-1988.
95. Kerkhof M., Steyerberg E.W., Kusters J.G., et al. Aneuploidy and high expression of p53 and Ki67 is associated with neoplastic progression in Barrett esophagus. Cancer Biomark 2008, 4(1):1-10.
96. Sikkema M., Kerkhof M., Steyerberg E.W., et al. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study. Am J Gastroenterol 2009, 104(11):2673-2680.
97. Kastelein F., Biermann K., Steyerberg E.W., et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut 2013, 62(12):1676-1683.
98. Sandborn W.J., Hanauer S., Van Assche G., et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. JCrohns Colitis 2014, 8(9):927-935.
99. Wong D.J., Paulson T.G., Prevo L.J., et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001, 61(22):8284-8289.
100. Schulmann K., Sterian A., Berki A., et al. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 2005, 24(25):4138-4148.
101. Prasad G.A., Wang K.K., Halling K.C., et al. Correlation of histology with biomarker status after photodynamic therapy in Barrett esophagus. Cancer 2008, 113(3):470-476.
102. Prasad G.A., Wang K.K., Halling K.C., et al. Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology 2008, 135(2):370-379.
103. Timmer M.R., Brankley S.M., Gorospe E.C., et al. Prediction of response to endoscopic therapy of Barrett's dysplasia by using genetic biomarkers. Gastrointest Endosc 2014, 80(6):984-991.
104. Sato F., Jin Z., Schulmann K., et al. Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features. PLoS One 2008, 3:e1890.
105. Xu E., Gu J., Hawk E.T., et al. Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis 2013, 34(12):2750-2756.
106. Jin Z., Cheng Y., Olaru A., et al. Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors. Int J Cancer 2008, 123(10):2331-2336.
107. Kaz A.M., Wong C.J., Luo Y., et al. DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses. Epigenetics 2011, 6(12):1403-1412.
108. Jin Z., Cheng Y., Gu W., et al. Amulticenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res 2009, 69(10):4112-4115.
109. Wang J.S., Guo M., Montgomery E.A., et al. DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett's esophagus. Am J Gastroenterol 2009, 104(9):2153-2160.
110. El-Serag H.B., Aguirre T.V., Davis S., et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004, 99(10):1877-1883.
111. Kastelein F., Spaander M.C., Steyerberg E.W., et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2013, 11(4):382-388.
112. Hillman L.C., Chiragakis L., Shadbolt B., et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004, 180(8):387-391.
113. Cooper B.T., Chapman W., Neumann C.S., et al. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Aliment Pharmacol Ther 2006, 23(6):727-733.
114. Hvid-Jensen F., Pedersen L., Funch-Jensen P., et al. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients. Aliment Pharmacol Ther 2014, 39(9):984-991.
115. Singh S., Garg S.K., Singh P.P., et al. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Gut 2014, 63(8):1229-1237.
116. Hong M.K., Laskin W.B., Herman B.E., et al. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus. Cancer 1995, 75(2):423-429.
117. Peters F.T., Ganesh S., Kuipers E.J., et al. Epithelial cell proliferative activity of Barrett's esophagus: methodology and correlation with traditional cancer risk markers. Dig Dis Sci 1998, 43(7):1501-1506.
118. Ouatu-Lascar R., Fitzgerald R.C., Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999, 117(2):327-335.
119. Peters F.T., Ganesh S., Kuipers E.J., et al. Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett esophagus. Scand J Gastroenterol 2000, 35(12):1238-1244.
120. Umansky M., Yasui W., Hallak A., et al. Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagus. Oncogene 2001, 20(55):7987-7991.
121. Thanan R., Ma N., Iijima K., et al. Proton pump inhibitors suppress iNOS-dependent DNA damage in Barrett's esophagus by increasing Mn-SOD expression. Biochem Biophys Res Commun 2012, 421(2):280-285.
122. Byrne J.P., Armstrong G.R., Attwood S.E. Restoration of the normal squamous lining in Barrett's esophagus by argon beam plasma coagulation. Am J Gastroenterol 1998, 93(10):1810-1815.
123. Brandt L.J., Blansky R.L., Kauvar D.R. Repeat laser therapy of recurrent Barrett's epithelium: success with anacidity. Gastrointest Endosc 1995, 41(3):267.
124. Kovacs B.J., Chen Y.K., Lewis T.D., et al. Successful reversal of Barrett's esophagus with multipolar electrocoagulation despite inadequate acid suppression. Gastrointest Endosc 1999, 49(5):547-553.
125. Ojima E., Fujimura T., Oyama K., et al. Chemoprevention of esophageal adenocarcinoma in a rat model by ursodeoxycholic acid. Clin Exp Med 2014, [Epub ahead of print].
126. Bozikas A., Marsman W.A., Rosmolen W.D., et al. The effect of oral administration of ursodeoxycholic acid and high-dose proton pump inhibitors on the histology of Barrett's esophagus. Dis Esophagus 2008, 21(4):346-354.
127. Garewal H.S., Sampliner R.E., Fennerty M.B. Chemopreventive studies in Barrett's esophagus: a model premalignant lesion for esophageal adenocarcinoma. JNatl Cancer Inst Monogr 1992, 51-54.
128. Sinicrope F.A., Broaddus R., Joshi N., et al. Evaluation of difluoromethylornithine for the chemoprevention of Barrett's esophagus and mucosal dysplasia. Cancer Prev Res (Phila) 2011, 4(6):829-839.
129. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008, 8(12):915-928.
130. Towler M.C., Hardie D.G. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007, 100(3):328-341.
131. Chak A., Buttar N.S., Foster N.R., et al. Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2015, 13(4):665-672.
132. Demierre M.F., Higgins P.D., Gruber S.B., et al. Statins and cancer prevention. Nat Rev Cancer 2005, 5(12):930-942.
133. Nguyen D.M., Richardson P., El-Serag H.B. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology 2010, 138(7):2260-2266.
134. Kastelein F., Spaander M.C., Biermann K., et al. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology 2011, 141(6):2000-2008. [quiz: e13-4].
135. Kantor E.D., Onstad L., Blount P.L., et al. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2012, 21(3):456-461.
136. Beales I.L., Vardi I., Dearman L. Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol 2012, 24(8):917-923.
137. Nguyen T., Khalaf N., Ramsey D., et al. Statin use is associated with a decreased risk of Barrett's esophagus. Gastroenterology 2014, 147(2):314-323.
138. Vinogradova Y., Coupland C., Hippisley-Cox J. Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer 2011, 11:409.
139. Singh P.P., Singh S. Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. Ann Oncol 2013, 24(7):1721-1730.
140. Brown L.M., Devesa S.S. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 2002, 11(2):235-256.
141. Pera M., Manterola C., Vidal O., et al. Epidemiology of esophageal adenocarcinoma. JSurg Oncol 2005, 92(3):151-159.
142. Engel L.S., Chow W.H., Vaughan T.L., et al. Population attributable risks of esophageal and gastric cancers. JNatl Cancer Inst 2003, 95(18):1404-1413.
143. Chow W.H., lot W.J., Vaughan T.L., et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. JNatl Cancer Inst 1998, 90(2):150-155.
144. Lagergren J., Bergström R., Nyrén O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999, 130(11):883-890.
145. Calle E.E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004, 4(8):579-591.
146. Nordenstedt H., El-Serag H. The influence of age, sex, and race on the incidence of esophageal cancer in the United States (1992-2006). Scand J Gastroenterol 2011, 46(5):597-602.
147. Steffen A., Schulze M.B., Pischon T., et al. Anthropometry and esophageal cancer risk in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2009, 18(7):2079-2089.
148. Nelsen E.M., Kirihara Y., Takahashi N., et al. Distribution of body fat and its influence on esophageal inflammation and dysplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2012, 10(7):728-734. [quiz: e61-2].
149. Malhi H., Gores G.J., Katzka D.A., et al. Mo1898 macrophage related inflammation and phenotype modulation in Barrett's esophagus. Gastroenterology 2013, 144(5):S-688.
150. Mehta S.P., Boddy A.P., Cook J., et al. Effect of n-3 polyunsaturated fatty acids on Barrett's epithelium in the human lower esophagus. Am J Clin Nutr 2008, 87(4):949-956.
151. Spechler S.J., Lee E., Ahnen D., et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001, 285(18):2331-2338.
152. Wang J.S., Varro A., Lightdale C.J., et al. Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett's esophagus. Am J Gastroenterol 2010, 105(5):1039-1045.